Combination therapy effective for patients with cholangiocarcinoma marked by BRAF mutations

Combination therapy effective for patients with cholangiocarcinoma marked by BRAF mutations

Combination therapy effective for patients with cholangiocarcinoma marked by BRAF mutations

In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in patients with cholangiocarcinoma marked by the BRAF V600E mutation.